Skip to main content

This is a preprint.

It has not yet been peer reviewed by a journal.

The National Library of Medicine is running a pilot to include preprints that result from research funded by NIH in PMC and PubMed.

medRxiv logoLink to medRxiv
[Preprint]. 2021 Jun 1:2021.05.31.21255594. [Version 1] doi: 10.1101/2021.05.31.21255594

Signatures of mast cell activation are associated with severe COVID-19

Janessa Tan, Danielle E Anderson, Abhay P S Rathore, Aled O’Neill, Chinmay Kumar Mantri, Wilfried A A Saron, Cheryl Lee, Chu Wern Cui, Adrian E Z Kang, Randy Foo, Shirin Kalimuddin, Jenny G Low, Lena Ho, Paul Tambyah, Thomas W Burke, Christopher W Woods, Kuan Rong Chan, Jörn Karhausen, Ashley L St John
PMCID: PMC8183010  PMID: 34100020

Abstract

Lung inflammation is a hallmark of Coronavirus disease 2019 (COVID-19) in severely ill patients and the pathophysiology of disease is thought to be immune-mediated. Mast cells (MCs) are polyfunctional immune cells present in the airways, where they respond to certain viruses and allergens, often promoting inflammation. We observed widespread degranulation of MCs during acute and unresolved airway inflammation in SARS-CoV-2-infected mice and non-human primates. In humans, transcriptional changes in patients requiring oxygen supplementation also implicated cells with a MC phenotype. MC activation in humans was confirmed, through detection of the MC-specific protease, chymase, levels of which were significantly correlated with disease severity. These results support the association of MC activation with severe COVID-19, suggesting potential strategies for intervention.

Full Text Availability

The license terms selected by the author(s) for this preprint version do not permit archiving in PMC. The full text is available from the preprint server.


Articles from medRxiv are provided here courtesy of Cold Spring Harbor Laboratory Preprints

RESOURCES